A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults
Status:
Completed
Trial end date:
2021-01-14
Target enrollment:
Participant gender:
Summary
This study is designed to assess safety, tolerability, pharmacokinetics (PK), formulation
(liquid and solid oral forms) and food effect of ABI-H3733 in healthy participants. Part 1
includes evaluation of the safety, tolerability, and PK of ABI-H3733 during single ascending
dose (SAD) and multiple-ascending dose (MAD) administration of the oral liquid formulation.
Part 2 includes assessment of a solid dosage formulation of ABI-H3733 in participants under
fasted conditions or after a high-fat meal. Optional cohorts may be enrolled in Parts 1 and 2
of the study to explore additional dose levels, solid oral dosage formulations, or for cohort
expansion.